Published on
October 18, 2021

H.C. Wainwright & Co. Initiates Coverage on atai Life Sciences, With Buy Rating And US$40 Price Target

H.C. Wainwright is initiating coverage of atai Life Sciences with a Buy rating and $40/share price target. atai is aiming to bring meaningful change to mental health challenges through psychedelic derived medicines and digital therapeutics.